The importance of the innate immune response as both the first line of defense against infection and a powerful trigger of adaptive immunity, and the definition of signaling pathways involved with this response, have led to intense testing of individual members of these pathways as molecular adjuvants. However, in the case of viral infection, the complete innate immune response is triggered by the presence of viral particles and their constituent components. Our approach is based on the idea that the viral particle itself, if it could be made safe and applicable to a wide range of vaccine modalities, would be a broad and effective inducer of innate immunity, in other words, an excellent adjuvant. Our studies to date indicate that propagation-defective Venezuelan equine encephalitis virus (VEE) replicon particles safely exhibit potent systemic and mucosal adjuvant activity when administered with subunit or inactivated vaccines. To build on these results with the goal of producing a safe and effective second generation adjuvant for biodefense, we propose the following four aims:
Aim 1 - to further define VEE adjuvant activity in mice;
Aim 2 - with our collaborators, to test adjuvant activity for specific biodefense vaccines, including avian influenza, poxviruses, Rift Valley Fever virus, Guanarito and Junin hemorrhagic fever viruses, and F. tularensis;
Aim 3 - in collaboration with the Center for Comparative Medicine at U.C.-Davis, to determine the level of adjuvant activity in primates;
and Aim 4 - to develop a scalable manufacturing process for adjuvant production. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI070976-03
Application #
7490414
Study Section
Special Emphasis Panel (ZAI1-LR-M (M1))
Program Officer
Leitner, Wolfgang W
Project Start
2006-09-01
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
3
Fiscal Year
2008
Total Cost
$1,141,009
Indirect Cost
Name
Global Vaccines, Inc.
Department
Type
DUNS #
607832719
City
Research Triangle Park
State
NC
Country
United States
Zip Code
27709
Steil, Benjamin P; Jorquera, Patricia; Westdijk, Janny et al. (2014) A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 32:558-63
Westdijk, Janny; Koedam, Patrick; Barro, Mario et al. (2013) Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 31:1298-304
Tonkin, Daniel R; Whitmore, Alan; Johnston, Robert E et al. (2012) Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine 30:4532-42
Brooke, Christopher B; Schafer, Alexandra; Matsushima, Glenn K et al. (2012) Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection. J Gen Virol 93:797-806
Schafer, Alexandra; Brooke, Christopher B; Whitmore, Alan C et al. (2011) The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J Virol 85:10682-90
Carroll, Timothy D; Matzinger, Shannon R; Barro, Mario et al. (2011) Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques. Vaccine 29:931-40
Tonkin, Daniel R; Jorquera, Patricia; Todd, Tracie et al. (2010) Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 28:3238-46
Thompson, Joseph M; Nicholson, Michael G; Whitmore, Alan C et al. (2008) Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol 181:574-85
Thompson, Joseph M; Whitmore, Alan C; Staats, Herman F et al. (2008) The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26:4998-5003
Thompson, Joseph M; Whitmore, Alan C; Staats, Herman F et al. (2008) Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 26:4267-75